Printer Friendly

MARION MERRELL DOW STATEMENT ON U.S. BIOSCIENCE

 MARION MERRELL DOW STATEMENT ON U.S. BIOSCIENCE
 KANSAS CITY, Mo. Jan. 30 /PRNewswire/ -- Marion Merrell Dow Inc.


(NYSE: MKC) today issued the following statement in conjunction with a filing with the Securities and Exchange Commission disclosing plans to sell all of the shares of the common stock it holds in U.S. Bioscience:
 "The decision to sell our equity interest is in no way intended to reflect negatively on what we feel are the strong fundamentals of U.S. Bioscience and the excellent potential of its new product pipeline. The initial investment in U.S. Bioscience was made by Marion Laboratories Inc. prior to its merger with Merrell Dow Pharmaceuticals Inc. and envisioned the possible future acquisition of U.S. Bioscience as a means of entry into the oncology market. This investment was unique in that it did not include specific product marketing rights and, thus, represented an equity investment only. As a result of the merger, which has provided Marion Merrell Dow with access to a number of new products, including several in oncology, the acquisition of U.S. Bioscience is no longer an element of the company's long-range strategic plan. Therefore, Marion Merrell Dow has made the decision to sell its interest in U.S. Bioscience through an underwritten public offering and utilize the proceeds for other corporate purposes."
 Marion Merrell Dow is a global pharmaceutical firm whose business activities focus on the discovery, development, manufacturing and marketing of prescription and over-the-counter pharmaceutical products. The company markets more than 140 products, predominantly in the United States and seven other countries in North America, Europe and the Pacific Basin.
 -0- 1/30/92
 /CONTACT: Larry W. Wheeler or David M. Thompson both of Marion Merrell Dow, 816-966-4000/
 (MKC) CO: Marion Merrell Dow Inc. ST: Missouri IN: MTC SU:


BB -- DV008 -- 5392 01/30/92 15:51 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 30, 1992
Words:309
Previous Article:HALLIBURTON PURCHASE OF TELEDYNE MERLA PROPOSED
Next Article:SECURITY FINANCIAL REPORTS FIRST QUARTER RESULTS
Topics:


Related Articles
MARION MERRELL DOW ACQUIRES GERMAN PHARMACEUTICAL COMPANY
IMMULOGIC AND MARION MERRELL DOW SIGN COLLABORATION AGREEMENT TO COMMERCIALIZE IMMULOGIC'S ALLERVAX ALLERGY PRODUCTS
MARION MERRELL DOW PROPOSES THREE NEW MEMBERS TO JOIN ITS BOARD OF DIRECTORS
ALZA, CYANAMID, ELAN AND MARION MERRELL CONCLUDE AGREEMENTS AND REACH AN OUT-OF-COURT SETTLEMENT
MARION MERRELL DOW COMMITS TO MAJOR EXPANSION OF AFFYMAX ALLIANCE
SCIOS NOVA INC. RAISES $7.95 MILLION THROUGH EXERCISE OF WARRANTS
MARION MERRELL DOW COMMENTS ON COURT CASE
MARION MERRELL DOW AND KODAMA LAUNCH COLLABORATION FOR JAPANESE MARKET
MARION MERRELL DOW SIMPLIFIES GLOBAL BUSINESS STRUCTURE, NAMES LEADERS
MARION MERRELL DOW K.K. INCREASES OWNERSHIP IN KODAMA

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters